Chinook Therapeutics CVR
13F holders, Q1 2026 (March 31)2holders
1new positions
1sold out
$0.00avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Chinook Therapeutics CVR in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holders were Rhumbline Advisers ($0) and Ascentis Independent Advisors ($0).
- Company
- Chinook Therapeutics CVR
- CUSIP
- 169CVR016
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 30 shares bought and 231 shares sold, net −201 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Rhumbline Advisers | 0.00% | Reduce -0.3% | 87,210 | $0 |
| Ascentis Independent Advisors | 0.00% | New | 30 | $0 |
"% of holder's portfolio" is CHINOOK THERAPEUTICS CVR's weight in each manager's 13F, not the share of Chinook Therapeutics CVR the manager owns.